June 13th, 2024

PMDA's Vision in New (Fifth) Mid-term Targets - International Vision -


Yoshiaki Maruyama, Ph.D.

Director,

Office of Cellular and Tissue-based Products PMDA, Japan

DISCLAIMER : The contents of this presentation represent the view of this presenter only, and do not represent the views and/or policies of the PMDA

PMDA Enters a New Stage on its 20th Anniversary



Study Group on Pharmaceutical Regulations to Strengthen Drug Discovery and Ensure Stable Supply (MHLW)

(Jul 10, 2023 – Mar 21, 2024)

Considering the pharmaceutical affairs regulations in order to eliminate drug loss issues, ensure stable supply and accelerate pediatric drugs development

Considerations

Promotion of development	How to designate orphan drugs Pharmaceutical reviews that contribute to promote development of pediatric drugs		Jul 10, 2023 Aug 7, 2023; Sep 13, Dec
Clinical trials	Arrangement of necessity of Japanese data for approval review in Japan Introduction of further efficiency in trials (ecosystem)	ב	13, Feb 8, 2024 Mar 12, 2024
Post-market safety measures	Post marketing use-results surveys Use of real world data in regulatory affairs system		Jan 12, Mar 12, 2024 Oct 13, Nov 15, 2023
Quality	Regulatory reviews on manufacturing methods of drugs		Nov 15, 2023
Information dissemination	Disseminating the information on Japanese regulatory system around the sticals and Medical Devices (only in Japanese) https://www.mhlw.go.jp/stf/shingi/other-iyaku		

PMDA's International Hubs



Establishment of PMDA's international hubs to enhance international contribution/capability for regulatory proposal



PMDA's 5th mid-term plan

Thank you very much!!

Please also see below information on the support of development in Japan

Reference materials on development in Japan for overseas ventures





https://www.pmda.go.jp/files/000266927.pdf

Regenerative Medical Products



1. Regulatory Framework

Regenerative medicine, which is expected to overcome intractable and serious diseases, is expected to play an important role in conventional medicine worldwide. The Japanese government must implement comprehensive policies to promote the development of regenerative medicine, inform the public, and increase public acceptance, and ensure that medical professionals and investigators cooperate with the policies. In this background, two regulatory frameworks for regenerative medicine, "<u>The Act on the Safety of Regenerative Medicine</u> *¬*]" (ASRM) and the "<u>Pharmaceuticals, Medical Devices, and Other Therapeutic Products Act</u> *¬*]" (PMD Act), came into effect in November 2014. The ASRM sets out legal regulations not only for research, but also for the daily medical practice of cell therapy, which had previously been under the jurisdiction of the <u>Medical Practitioners' Act</u> *¬*] and the <u>Medical Care Act</u> *¬*].

The PMD Act regulates the commercialization of regenerative medical products. Regenerative medical products in the PMD Act are defined as:

a. Processed (more than minimal manipulation) live human/animal cells that are intended to be used for either

• reconstruction, repair, or formation of structures or functions of the human body

https://www.pmda.go.jp/english/review-services/reviews/0003.html